Troponin T Serum Level Is Not Associated with the Location and Volume of Acute Brain Infarction (P5.133)

OBJECTIVE: To investigate the possible correlation between the location and volume of brain infarction and the cardiac troponin T (cTnT) serum level in AIS patients. BACKGROUND: cTnT is frequently elevated in in acute ischemic stroke patients. However, the relationship, if any, between the cTnT level and brain infarction remains to be established. DESIGN/METHODS: The prospective hospital-based study (Clinicaltrials.gov No.NCT01541163) consisted of consecutive AIS patients admitted within 12h of stroke onset. The location and volume of the acute brain ischemic lesion was assessed with magnetic resonance imaging. Standard laboratory tests, including cTnT and repeated electrocardiograms, were performed at admission and after 4h. Correlations between the cTnT level and the location and volume of brain infarction and baseline parameters were tested with a Spearman correlation coefficient. Univariate and multiple logistic regression analysis (LRA) were used to determine the possible predictors of cTnT elevation. RESULTS: Out of the 200 enrolled patients, elevated cTnT was present in 71 (36[percnt]). No correlation was found between the cTnT serum levels and the location ( P >0.05) nor volume of brain infarction ( P =0.48). LRA identified creatinine (OR:1.26 per 10µmol/L increase; 95[percnt]CI:1.043-1.524), NT-proBNP (OR:1.05 per 100μg/L increase; 95[percnt]CI:1.018-1.093) and male gender (OR:3.674; 95[percnt]CI:1.025-13.164) as significant independent predictors of pathological elevation of cTnT. CONCLUSIONS: Although elevated cTnT serum level is relatively frequent in AIS patients within the first 12h of stroke onset, it is not related to the location or volume of brain infarction. Study Supported by: MHCR grants NT/11046-6/2010, NT/14288-3/2013 and by RVO FNOL 00098892. Disclosure: Dr. Kral has nothing to disclose. Dr. Sanak has received personal compensation for activities with Boehringer Ingelheim Pharmaceuticals, Inc. as a scientific advisory board member and/or speaker. Dr. Veverka has nothing to disclose. Dr. Hutyra has nothing to disclose. Dr. Cechakova has nothing to disclose. Dr. Skoloudik has nothing to disclose. Dr. Kanovsky has nothing to disclose.